



China's National Medical Products Administration Approves Authorization of Commercialization for Miconazole Muco-adhesive Buccal Tablet

January 15, 2021

SciClone Pharmaceuticals and Vectans Pharma announced today that China's National Medical Products Administration (NMPA) has granted the approval of commercialization for the Miconazole Muco-adhesive Buccal Tablet, Oravig[®], for the topical treatment of oropharyngeal candidiasis of adult human. Oravig[®] has already been approved for commercialization in several overseas countries.

Mr. Hong Zhao, Chief Executive Officer of SciClone Pharmaceuticals, said: "Candida is an opportunistic pathogen, patients with immune dysfunction are prone to suffer from oropharyngeal candidiasis, especially patients with haematological tumours, patients undergoing radiotherapy for head and neck cancers and those infected by HIV. At present, mostly are systemic antifungal drugs on the market, which cannot effectively meet the needs of China's oropharyngeal candidiasis that only require topical treatment. Oravig[®] is muco-adhesive buccal tablets which is contained Miconazole with unique patented dosage form that could provide the high and sustained levels of Miconazole concentrations, which would enhance patient compliance with once daily administration. Its launch will bring more convenient and effective treatment to patients with oropharyngeal candidiasis. "

Mr. Jérôme Théron, Chief Executive Officer of Vectans Pharma, said: "We are delighted to see the approval of commercialization of Oravig[®] in China, which is an important milestone in our collaboration. We are looking forward to continuing our cooperation with SciClone in the Chinese market".

About SciClone Pharmaceuticals

SciClone Pharmaceuticals (Holdings) Limited is a biopharmaceutical company with an integrated platform for product development and commercialization. We strategically focus on some of the severe and fast-growing therapeutic areas with significant unmet medical needs in China, primarily including oncology and severe infection. Leveraging our integrated platform, we strive to develop and commercialize a balanced portfolio of high-quality marketed products, including our proprietary product, Zadaxin, and pipeline drugs in our focused therapeutic areas.

For more information about SciClone Pharmaceuticals, please visit: <http://www.sciclone.com/>

About Vectans Pharma

Vectans Pharma is an international pharmaceutical company offering new therapeutic perspectives to the pharmaceutical industry thanks to an innovative drug delivery system (Lauriad Technology). Our drugs – Sitavig® (acyclovir lauriad) and Loramyc®/Oravig®/Oravi® (miconazole lauriad) - have been developed based on this technology which offers a new route of administration aiming to improve the benefit of patients and are already commercialized through license agreements in the US, Europe and Japan.

For more information about Vectans Pharma, please visit <https://www.vectanspharma.com/>